IL15 and neoplasm: All three NK cell therapies (MOCK, CD70-CAR, and CD70-CAR-IL-15) significantly delayed tumor growth over time and improved survival compared to the untreated control group (Median survival untreated: 18 days, MOCK: 21.5 days, CD70-CAR: 21.5 days, and CD70-CAR-IL-15: 27 days; Fig. 4C, D, E).